Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Talvey Seen as Promising Option for Hard-to-Treat Multiple Myeloma: Oncologist
September 8, 2025
- KM Biologics Developing Higher-Yield Liquid Immunoglobulin to Boost Efficiency and Supply
September 8, 2025
- Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
- Ferring Files for Japan Approval of Bladder Cancer Gene Therapy
September 8, 2025
- Kaken’s Onychomycosis Drug Grabs German Approval
September 8, 2025
- Japan Ethical Drug Sales Inch Up 0.7% in July: Crecon
September 8, 2025
- Nichi-Iko Shows Signs of Recovery but Restructuring Still Underway: CEO
September 5, 2025
- And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
- New Study of Vasomune-Partnered AV-001 Cleared in Canada: AnGes
September 5, 2025
- Keytruda Top-Selling Drug in Japan for 23 Months Running: Encise
September 5, 2025
- Eisai Begins FDA Rolling Submission for Leqembi SC for Starting Dose
September 4, 2025
- FDA Accepts Xocova NDA for COVID Post-Exposure Prophylaxis
September 4, 2025
- Bayer Pushes Cross-Border Open Innovation with New Co.Lab Connect Program
September 4, 2025
- ASKA Repeats Request to Dalton after Dismissive Email on Stake Plan
September 3, 2025
- Kaken’s Hyperhidrosis Drug Ecclock Gets Approval in South Korea
September 3, 2025
- Mitsubishi Tanabe Releases OD Tablet Form of Canalia in Japan
September 3, 2025
- Fuji, Nitto Strike Sales Deal for Eylea Biosimilar, Eye November Listing
September 2, 2025
- Shionogi Completes Full Takeover of Torii under JT Deal
September 2, 2025
- Teva Takeda Renamed as T’s Pharma
September 2, 2025
- FDA Clears Leqembi Autoinjector; Launch Set for Oct. 6
September 2, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…